Cytek Biosciences (CTKB) Assets Average (2021 - 2026)

Cytek Biosciences has reported Assets Average for 6 years, with the latest figure at $455.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 7.27% year-over-year to $455.3 million; the trailing twelve-month figure through Mar 2026 stood at $455.3 million (down 7.27% YoY), and the FY2025 full-year result was $480.5 million, down 3.31% from the prior year.
• Assets Average for Q1 2026 stood at $455.3 million, down from $478.2 million in the prior quarter.
• The five-year high for Assets Average was $524.8 million in Q2 2023, with the low at $455.3 million in Q1 2026.
• Historically, Assets Average has averaged $495.1 million across 5 years, with a median of $493.3 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average surged 44.92% — and 2026, when it decreased 7.27%.
• Cytek Biosciences' Assets Average stood at $509.4 million in 2022, then decreased by 0.48% to $506.9 million in 2023, then retreated by 2.28% to $495.4 million in 2024, then decreased by 3.46% to $478.2 million in 2025, then dropped by 4.79% to $455.3 million in 2026.
• The last three Assets Average figures came in at $455.3 million (Q1 2026), $478.2 million (Q4 2025), and $494.1 million (Q3 2025), per Business Quant data.